Abstract
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
Walter P Maksymowych, Robert Landewe, Maarten Boers, Patrick Garnero, Piet Geusens, Hani El-Gabalawy, Dick Heinegard, Virginia B Kraus, Virginia Krause, Stefan Lohmander, John Matyas, Tore Saxne and Desiree van der Heijde
The Journal of Rheumatology March 2007, 34 (3) 634-640;
Walter P Maksymowych
Robert Landewe
Maarten Boers
Patrick Garnero
Piet Geusens
Hani El-Gabalawy
Dick Heinegard
Virginia B Kraus
Virginia Krause
Stefan Lohmander
John Matyas
Tore Saxne
In this issue
The Journal of Rheumatology
Vol. 34, Issue 3
1 Mar 2007
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
Walter P Maksymowych, Robert Landewe, Maarten Boers, Patrick Garnero, Piet Geusens, Hani El-Gabalawy, Dick Heinegard, Virginia B Kraus, Virginia Krause, Stefan Lohmander, John Matyas, Tore Saxne, Desiree van der Heijde
The Journal of Rheumatology Mar 2007, 34 (3) 634-640;
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
Walter P Maksymowych, Robert Landewe, Maarten Boers, Patrick Garnero, Piet Geusens, Hani El-Gabalawy, Dick Heinegard, Virginia B Kraus, Virginia Krause, Stefan Lohmander, John Matyas, Tore Saxne, Desiree van der Heijde
The Journal of Rheumatology Mar 2007, 34 (3) 634-640;